West Pharmaceutical Services, Inc. (WST) Tops Q3 EPS by 1c; Lowers FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $362.31 -1.17%
EPS Growth %: +11.7%
Financial Fact:
Gross profit: 121.1M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +11.7%
Financial Fact:
Gross profit: 121.1M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q3 EPS of $0.53, $0.01 better than the analyst estimate of $0.52. Revenue for the quarter came in at $293.6 million versus the consensus estimate of $289.25 million.
Sees FY2011 EPS of $2.28-$2.35, versus prior guidance of $2.30-$2.40 and the consensus of $2.35. Sees FY2011 revenue of $1.18-$1.20 billion, versus prior guidance of $1.17-$1.20 billion and the consensus of $1.19 billion.
Sees FY2011 EPS of $2.28-$2.35, versus prior guidance of $2.30-$2.40 and the consensus of $2.35. Sees FY2011 revenue of $1.18-$1.20 billion, versus prior guidance of $1.17-$1.20 billion and the consensus of $1.19 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Intuit holds investor day, reaffirms fiscal 2027 guidance
- Fluence Energy cuts fiscal 2026 revenue outlook on supply chain woes
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
